TY - JOUR
T1 - Inactivation and Inducible Oncogenic Mutation of p53 in Gene Targeted Pigs
AU - Leuchs, Simon
AU - Saalfrank, Anja
AU - Merkl, Claudia
AU - Flisikowska, Tatiana
AU - Edlinger, Marlene
AU - Durkovic, Marina
AU - Rezaei, Nousin
AU - Kurome, Mayuko
AU - Zakhartchenko, Valeri
AU - Kessler, Barbara
AU - Flisikowski, Krzysztof
AU - Kind, Alexander
AU - Wolf, Eckhard
AU - Schnieke, Angelika
PY - 2012/10/5
Y1 - 2012/10/5
N2 - Mutation of the tumor suppressor p53 plays a major role in human carcinogenesis. Here we describe gene-targeted porcine mesenchymal stem cells (MSCs) and live pigs carrying a latent TP53R167H mutant allele, orthologous to oncogenic human mutant TP53R175H and mouse Trp53R172H, that can be activated by Cre recombination. MSCs carrying the latent TP53R167H mutant allele were analyzed in vitro. Homozygous cells were p53 deficient, and on continued culture exhibited more rapid proliferation, anchorage independent growth, and resistance to the apoptosis-inducing chemotherapeutic drug doxorubicin, all characteristic of cellular transformation. Cre mediated recombination activated the latent TP53R167H allele as predicted, and in homozygous cells expressed mutant p53-R167H protein at a level ten-fold greater than wild-type MSCs, consistent with the elevated levels found in human cancer cells. Gene targeted MSCs were used for nuclear transfer and fifteen viable piglets were produced carrying the latent TP53R167H mutant allele in heterozygous form. These animals will allow study of p53 deficiency and expression of mutant p53-R167H to model human germline, or spontaneous somatic p53 mutation. This work represents the first inactivation and mutation of the gatekeeper tumor suppressor gene TP53 in a non-rodent mammal.
AB - Mutation of the tumor suppressor p53 plays a major role in human carcinogenesis. Here we describe gene-targeted porcine mesenchymal stem cells (MSCs) and live pigs carrying a latent TP53R167H mutant allele, orthologous to oncogenic human mutant TP53R175H and mouse Trp53R172H, that can be activated by Cre recombination. MSCs carrying the latent TP53R167H mutant allele were analyzed in vitro. Homozygous cells were p53 deficient, and on continued culture exhibited more rapid proliferation, anchorage independent growth, and resistance to the apoptosis-inducing chemotherapeutic drug doxorubicin, all characteristic of cellular transformation. Cre mediated recombination activated the latent TP53R167H allele as predicted, and in homozygous cells expressed mutant p53-R167H protein at a level ten-fold greater than wild-type MSCs, consistent with the elevated levels found in human cancer cells. Gene targeted MSCs were used for nuclear transfer and fifteen viable piglets were produced carrying the latent TP53R167H mutant allele in heterozygous form. These animals will allow study of p53 deficiency and expression of mutant p53-R167H to model human germline, or spontaneous somatic p53 mutation. This work represents the first inactivation and mutation of the gatekeeper tumor suppressor gene TP53 in a non-rodent mammal.
UR - http://www.scopus.com/inward/record.url?scp=84867171118&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0043323
DO - 10.1371/journal.pone.0043323
M3 - Article
C2 - 23071491
AN - SCOPUS:84867171118
SN - 1932-6203
VL - 7
JO - PLoS ONE
JF - PLoS ONE
IS - 10
M1 - e43323
ER -